Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSamsun University
About this trial
Fluid resuscitation is a critical component of sepsis treatment. Research has shown that intravenous (IV) fluid therapy in sepsis positively impacts cardiac output and thereby oxygen (O2) delivery through a complex interaction of central venous pressure, right atrial pressure, venous resistance, ventricular compliance, cardiac contractility, and systemic vascular resistance. The 2021 sepsis prevention guidelines recommend balanced crystalloids as first-line therapy. However, no studies in the literature have evaluated the effect of albumin on O2 delivery. In our study, the investigators aim to assess the impact of albumin replacement on O2 delivery in sepsis patients in the intensive care unit.
Eligibility criteria
Qualifiers
Followed up with a diagnosis of sepsis,
over 18 years old
Patients who were diagnosed with hypo-albuminemia after more than 4L/day fluid resuscitation and underwent albumin replacement
Disqualifiers
Consent is not given by the patient or his/her guardian,
The initial cause of shock was hypovolemic, cardiogenic or obstructive shock.
Pregnancy or suspected pregnancy
Peripheral limb or severe organ ischemia with peripheral artery disease
Trial design
Treatments tested in this trial
- Not listed
Trial groups
45 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov